Standard Biotools Inc (LAB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $279.27M
Last updated: Nov 17, 2026 at 11:02 AM ET
Standard Biotools Inc (LAB) Financials: Revenue, Profit and Cash Flow
Standard Biotools reported revenue of $85.33M for the fiscal year ended Dec 31, 2025, down 6.2% from the year before. That year, net income was -$74.90M with a net margin of -87.8%, operating cash flow was -$74.34M and free cash flow was -$82.65M. The quarter ended Sep 30, 2026 had revenue of $19.39M and net income of $13.48M.
Revenue and Margins
The net margin was -87.8% in the fiscal year ended Dec 2025, the lowest of the 8 years shown with a net margin. Over the 9 years to Dec 2025, revenue fell from $193.45M, a compound annual decline of 8.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $85.33M | -6.2% | 49.9% | -129.2% | -87.8% |
| Dec 2024 | $91.01M | -14.4% | 49.3% | -140.1% | -152.6% |
| Dec 2023 | $106.34M | +8.6% | 47.4% | -72.0% | -70.2% |
| Dec 2022 | $97.95M | -25.0% | 37.8% | -118.6% | -194.1% |
| Dec 2021 | $130.58M | -5.5% | 53.1% | -51.7% | -45.4% |
| Dec 2020 | $138.14M | +17.8% | 60.3% | -36.9% | -38.4% |
| Dec 2019 | $117.24M | +3.8% | 54.8% | -44.2% | -55.3% |
| Dec 2018 | $112.96M | -39.4% | 54.6% | -42.6% | -52.2% |
| Dec 2017 | $186.34M | -3.7% | 27.9% | -31.3% | -32.5% |
| Dec 2016 | $193.45M | N/A | 30.2% | -37.8% | -39.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.33M | $91.01M | $106.34M | $97.95M | $130.58M | $138.14M | $117.24M | $112.96M | $186.34M | $193.45M |
| Cost of revenue | $42.79M | $46.13M | $55.89M | $60.90M | $61.21M | $54.82M | $52.96M | $51.31M | -$34.44M | -$42.99M |
| Gross profit | $42.54M | $44.88M | $50.45M | $37.05M | $69.37M | $83.33M | $64.28M | $61.65M | $51.98M | $58.44M |
| Research and development | $25.99M | $28.83M | $25.95M | $37.38M | $37.94M | $36.46M | $31.64M | $30.03M | $30.83M | $38.41M |
| Operating income | -$110.25M | -$127.48M | -$76.60M | -$116.20M | -$67.46M | -$51.04M | -$51.84M | -$48.16M | -$58.36M | -$73.19M |
| Net income | -$74.90M | -$138.88M | -$74.66M | -$190.10M | -$59.24M | -$53.02M | -$64.79M | -$59.01M | -$60.53M | -$75.98M |
| EBITDA | -$97.52M | -$97.85M | -$61.29M | N/A | -$43.64M | -$32.04M | -$33.18M | -$22.58M | -$39.08M | -$56.14M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.39M | $20.10M | $21.15M | $3.22M | $19.55M | $21.76M | $20.22M | $890.00K | $22.09M | $22.49M | $45.54M | $28.19M |
| Gross profit | $10.83M | $10.54M | $11.31M | $2.69M | $9.48M | $10.63M | $11.05M | -$1.80M | $12.13M | $10.37M | $24.19M | $13.41M |
| Operating income | -$19.77M | -$25.39M | -$12.50M | -$18.64M | -$32.94M | -$25.70M | -$26.97M | -$10.34M | -$26.70M | -$30.26M | -$60.18M | -$21.39M |
| Net income | $13.48M | -$26.76M | $127.07M | $19.28M | -$34.69M | -$33.46M | -$26.03M | -$34.07M | -$26.94M | -$45.72M | -$32.16M | -$19.78M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $5.79M by $115.07M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $567.75M | $612.35M | $323.07M | $390.31M | $275.21M | $324.76M | $264.81M | $303.65M | $287.35M | $306.39M |
| Current assets | $454.26M | $375.88M | $158.22M | $208.81M | $72.07M | $117.66M | $96.10M | $127.11M | $94.80M | $96.67M |
| Cash and equivalents | $120.86M | $166.73M | $51.70M | $81.31M | $28.45M | $68.52M | $21.66M | $95.40M | $58.06M | $35.05M |
| Total liabilities | $143.46M | $140.62M | $159.87M | $160.52M | $180.62M | $185.71M | $111.20M | $231.53M | $256.42M | $253.16M |
| Short-term debt | $5.49M | $6.23M | $59.53M | $2.08M | $6.84M | $0 | $1.83M | $0 | $0 | $0 |
| Long-term debt | $299.00K | $299.00K | $3.98M | $62.81M | $64.21M | $54.22M | $53.82M | $172.06M | $195.24M | $194.95M |
| Shareholder equity | $424.29M | $471.72M | -$148.05M | -$81.47M | $94.60M | $139.05M | $153.61M | $72.12M | $30.93M | $53.23M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $635.33M | $627.22M | $639.11M | $567.75M | $539.64M | $556.97M | $579.60M | $612.34M | $681.54M | $708.73M | $777.67M | $323.07M |
| Total liabilities | $79.58M | $87.25M | $77.99M | $143.46M | $139.98M | $132.43M | $125.00M | $140.62M | $192.21M | $198.47M | $200.35M | $159.87M |
| Cash and equivalents | $267.49M | $270.03M | $265.77M | $118.21M | $129.42M | $158.62M | $150.88M | $166.73M | $210.65M | $269.81M | $287.06M | $51.70M |
| Shareholder equity | $555.75M | $539.97M | $561.12M | $424.29M | $399.66M | $424.54M | $454.60M | $471.72M | $489.33M | $510.26M | $577.32M | $163.20M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$74.34M | -$143.45M | -$43.29M | -$89.37M | -$44.06M | -$15.42M | -$35.21M | -$25.20M | -$24.10M | -$39.14M |
| Capital expenditures | $8.30M | $8.36M | $2.83M | $3.83M | $13.26M | $12.72M | $2.53M | $372.00K | $1.57M | $5.07M |
| Free cash flow | -$82.65M | -$151.81M | -$46.12M | -$93.19M | -$57.33M | -$28.13M | -$37.74M | -$25.57M | -$25.66M | -$44.20M |
| Dividends paid | N/A | N/A | N/A | N/A | $299.00K | N/A | $1.50M | N/A | N/A | N/A |
| Share repurchases | $0 | $40.49M | $5.41M | $13.11M | $79.00K | $684.00K | $1.89M | $2.86M | $0 | N/A |
| Investing cash flow | $27.41M | $363.17M | $20.24M | -$88.13M | -$11.95M | $39.98M | -$39.30M | $4.72M | $17.66M | $45.10M |
| Financing cash flow | $570.00K | -$102.62M | -$6.81M | $230.76M | $15.96M | $20.86M | $2.79M | $57.66M | $29.00M | $116.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.16M | -$10.31M | -$46.60M | -$1.19M | -$22.20M | -$20.67M | -$30.28M | -$14.06M | -$27.87M | -$39.05M | -$62.48M | -$14.06M |
| Capital expenditures | N/A | $344.00K | $570.00K | $476.00K | $886.00K | $1.89M | $5.05M | $3.38M | $2.25M | $1.94M | $781.00K | $78.00K |
| Free cash flow | N/A | -$10.65M | -$47.17M | -$1.67M | -$23.09M | -$22.55M | -$35.34M | -$17.44M | -$30.12M | -$40.99M | -$63.26M | -$14.14M |
Frequently Asked Questions About LAB
What is Standard Biotools' annual revenue?
Standard Biotools reported revenue of $85.33M for the fiscal year ended Dec 31, 2025.
How fast is Standard Biotools' revenue growing?
Revenue was down 6.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -4.5%.
Is Standard Biotools profitable?
No. Standard Biotools reported net income of -$74.90M for the fiscal year ended Dec 31, 2025, with a net margin of -87.8%.
How much free cash flow does LAB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$74.34M minus capital expenditures of $8.30M produced free cash flow of -$82.65M.
How much debt does Standard Biotools have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $299.00K, short-term debt of $5.49M and cash and equivalents of $120.86M.
LAB pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts